AdaptHealth Corp. (AHCO) · wyniki II kw. 2026 i wycena

Przy wzroście 3,0% rocznie (3-letni wzrost przychodów) wartość godziwa z modelu to $8.94 na akcję — kurs jest o 34% poniżej niej. Obecna cena zakłada wzrost o 1,0% rocznie.

1. Prognoza

   AHCO updated guidance to expect roughly half of that stranded cost to be removed within 12 months of closing the deal, which should lower expenses.

   Cytat ze źródła

   “Starting with our new capitated agreement, we navigated through one of the most ambitious operational undertakings by completing the largest... ...third, in April, we refinanced our credit facility with improved terms, further strengthening our balance sheet and providing financial and strategic flexibility. No HME company had ever taken on a capitated contract of this scale from an incumbent.”

2. Prognoza

   AHCO signed an agreement to sell its Diabetes Health business for $235 million to improve its growth rate and enhance its margin.

   Cytat ze źródła

   “We signed a definitive agreement to sell our Diabetes Health business for $235 million, a move that we expect will ultimately improve our growth rate, enhance our margin...”

Script and answers carried a similar tone, so the script's message held up under questioning.

Zdania, które wpłynęły na ton

“Our growth strategy is focused on improving our service levels in our core business, expanding our capitated relationships where it makes sense and growing the number of large health systems...”

“First, we delivered 16% organic growth with record volumes gains across the business.”

“Ultimately, these growing pains will make us a stronger, more efficient company.”